RET and cancer: BLU-667 has been shown to induce tumor regression in cancer models with RET mutations and fusions (Subbiah et al., 2018), dasatinib has been shown to reduce NB growth as early as 2009 (Vitali et al., 2009), and spebrutinib has antitumor activity in large B-cell lymphoma (Tanaka et al., 2020).